1e
19
1
49
2
2
18
1b
1d
18
2b
82
1d
2 29
1d
25
Roger B Cohen
88
82
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
3
2
4
b
1f
4d
Division of Hematology-Oncology
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
31 Office #10-139
Philadelphia, PA 19104
26
2e Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
31 Office #10-139
Philadelphia, PA 19104
2e
Office: 215-662-4469
32 Fax: 215-349-5326
24
f
32 Fax: 215-349-5326
24
13
Education:
21 9 A.B. 21 (Biochemical Sciences) c
3a Harvard College (magna cum laude), 1976.
21 9 M.D. 15 (Medicine) c
2f Harvard Medical School, 1980.
c
3
3
3
3
8d
Permanent link21 9 A.B. 21 (Biochemical Sciences) c
3a Harvard College (magna cum laude), 1976.
21 9 M.D. 15 (Medicine) c
2f Harvard Medical School, 1980.
c
2 29
21
1e
1d
24
2b
29
27
23
1d1 Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ.: Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy. Am J Clin Oncol Nov 2025.
23f Yegya-Raman N, Ko K, Han IS, Mitchell JD, Zou W, Ohri N, Jabbour SK, Mak RH, Robinson C, Levin WP, Barrett L, Xia C, Berlin E, Bravo P, Carli MD, Cohen R, Hutton S, Keltz J, Wang J, Fasan O, Nagda SN, Seo A, Smith AM, Sun L, Soike M, Kole AJ, Walls G, Feigenberg SJ, Ky B.: Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study. Clin Transl Radiat Oncol 56: 101070, Nov 2025.
192 Gobillot TA, Weinstein G, Cao A, Lee JJ, Brody RM, Basu D, O'Malley BW Jr, Farwell DG, Cannady S, Lin A, Lukens J, Gentile M, Newman JG, Chalian AA, Sun L, Lakshmipathy D, Cohen RB, Rasskeh CH, Rajasekaran K.: Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery. Laryngoscope Aug 2025.
1ff Theodore A Gobillot, Gregory Weinstein, Austin Cao, Jake J Lee, Robert M Brody, Devraj Basu, Bert W O'Malley Jr, D Gregory Farwell, Steven Cannady, Alexander Lin, John Lukens, Michelle Gentile, Jason G Newman, Ara A Chalian, Lova Sun, Deepak Lakshmipathy, Roger B Cohen, Christopher H Rasskeh, Karthik Rajasekaran: Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery. The Laryngoscope Aug 2025.
182 Cohen RB, Jimeno A, Hreno J, Sun L, Wallén-Öhman M, Millrud CR, Sanfridson A, Garcia-Ribas I.: Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors. Invest New Drugs May 2025.
1c2 Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L.: Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. JTO Clin Res Rep 6: 100851, May 2025.
241 Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB.: INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 31: 2617-2627, Apr 2025.
1dc Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D.: Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer. J Natl Cancer Inst 117: 1366-1376, Mar 2025.
2db Erin M. Bange, MD, MSCE, Kerry Q. Coughlin, MSW, Wenrui Li, PhD, Timothy J. Brown, MD, MSCE, Daniel Ragusano, MPH, Eesha Balar, Dhivya Arasappan, Michelle Nnaji, Elliot Kim, Corey Alban, BSN, RN, Sindhuja Uppuluri, Elizabeth Moriarty, BSN, RN, Tara Bange, MaT, Lindsey Zinck, PhD, RN, OCN, NEA-BC, David Smith, MS, Michael Josephs, James J. Harrigan, MD, PharmD, Roger B. Cohen, MD, Danielle Zubka, RN, Roy Rosin, MBA, Mohan Balachandran, MA, MS, Qi Long, PhD, Andrea Bilger, MPH, Lynn M. Schuchter, MD, Mira Mamtani, MD, MSEd, Lawrence N. Shulman, MD, Carmen E. Guerra, MD, MSCE, and Ronac Mamtani, MD, MSCE: A Text Message Intervention to Minimize the Time Burden of Cancer Care 22 NEJM Catal Innov Care Deliv 29 6(3), February 2025.
2c
7
1d
1f
Selected Publications
186 Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME.: Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC). Lung Cancer 213: 108936, Jan 2026.1d1 Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ.: Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy. Am J Clin Oncol Nov 2025.
23f Yegya-Raman N, Ko K, Han IS, Mitchell JD, Zou W, Ohri N, Jabbour SK, Mak RH, Robinson C, Levin WP, Barrett L, Xia C, Berlin E, Bravo P, Carli MD, Cohen R, Hutton S, Keltz J, Wang J, Fasan O, Nagda SN, Seo A, Smith AM, Sun L, Soike M, Kole AJ, Walls G, Feigenberg SJ, Ky B.: Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study. Clin Transl Radiat Oncol 56: 101070, Nov 2025.
192 Gobillot TA, Weinstein G, Cao A, Lee JJ, Brody RM, Basu D, O'Malley BW Jr, Farwell DG, Cannady S, Lin A, Lukens J, Gentile M, Newman JG, Chalian AA, Sun L, Lakshmipathy D, Cohen RB, Rasskeh CH, Rajasekaran K.: Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery. Laryngoscope Aug 2025.
1ff Theodore A Gobillot, Gregory Weinstein, Austin Cao, Jake J Lee, Robert M Brody, Devraj Basu, Bert W O'Malley Jr, D Gregory Farwell, Steven Cannady, Alexander Lin, John Lukens, Michelle Gentile, Jason G Newman, Ara A Chalian, Lova Sun, Deepak Lakshmipathy, Roger B Cohen, Christopher H Rasskeh, Karthik Rajasekaran: Outcomes of HPV+ Oropharyngeal Carcinoma of Unknown Primary Following Transoral Robotic Surgery. The Laryngoscope Aug 2025.
182 Cohen RB, Jimeno A, Hreno J, Sun L, Wallén-Öhman M, Millrud CR, Sanfridson A, Garcia-Ribas I.: Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors. Invest New Drugs May 2025.
1c2 Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L.: Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. JTO Clin Res Rep 6: 100851, May 2025.
241 Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB.: INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 31: 2617-2627, Apr 2025.
1dc Sannigrahi MK, Raghav L, Rich DJ, Schrank TP, Califano JA, Lukens JN, Sun L, Morgan IM, Cohen RB, Lin A, Liu X, Brown EJ, You J, Mirabello L, Mishra SK, Shimunov D, Brody RM, Pearson AT, Gimotty PA, Diab A, Jalaly JB, Basu D.: Tumor-intrinsic and immune-related features associated with treatment failure in human papillomavirus-related oropharyngeal cancer. J Natl Cancer Inst 117: 1366-1376, Mar 2025.
2db Erin M. Bange, MD, MSCE, Kerry Q. Coughlin, MSW, Wenrui Li, PhD, Timothy J. Brown, MD, MSCE, Daniel Ragusano, MPH, Eesha Balar, Dhivya Arasappan, Michelle Nnaji, Elliot Kim, Corey Alban, BSN, RN, Sindhuja Uppuluri, Elizabeth Moriarty, BSN, RN, Tara Bange, MaT, Lindsey Zinck, PhD, RN, OCN, NEA-BC, David Smith, MS, Michael Josephs, James J. Harrigan, MD, PharmD, Roger B. Cohen, MD, Danielle Zubka, RN, Roy Rosin, MBA, Mohan Balachandran, MA, MS, Qi Long, PhD, Andrea Bilger, MPH, Lynn M. Schuchter, MD, Mira Mamtani, MD, MSEd, Lawrence N. Shulman, MD, Carmen E. Guerra, MD, MSCE, and Ronac Mamtani, MD, MSCE: A Text Message Intervention to Minimize the Time Burden of Cancer Care 22 NEJM Catal Innov Care Deliv 29 6(3), February 2025.
2c